Department of Ophthalmology, Traditional Chinese Medicine Hospital of Kunshan, Kunshan, PR China.
Immunopharmacol Immunotoxicol. 2024 Oct;46(5):627-634. doi: 10.1080/08923973.2024.2390449. Epub 2024 Aug 12.
The aim of this study was to investigate the clinical use of sodium hyaluronate (SH) combined with pranoprofen in treating patients with dry eye.
A total of 117 patients with dry eye who were treated in the Traditional Chinese Medicine Hospital of Kunshan from March 2020 and May 2022 were included. According to the therapy approaches, they were treated with SH (SH group), pranoprofen (pranoprofen group), and SH combined with pranoprofen (joint group) ( = 39).
The effective rates of dry eye were 79.49%, 74.36% and 94.87% in the SH group, the pranoprofen group and the joint group, respectively ( < 0.05). After treatment, the tear BUT and SIT in the joint group were all prominently increased than those in the other two groups ( < 0.05). The corneal fluorescein staining and dry eye symptom scores in the joint group after treatment were dramatically lower than those in the other two groups ( < 0.001). After treatment, the visual contrast sensitivity (12 c/d, 18 c/d and 24 c/d) in the joint group was markedly higher than those in the other two groups ( < 0.001). The CPR, TNF-α, IFN-γ and IL-1β levels in the joint group were notably decreased than those in other two groups ( < 0.001). After treatment, the VRQOL quality-of-life scores in the joint group were significantly higher than those in the other two groups ( < 0.05).
SH combined with pranoprofen showed clear therapeutic benefit in treating dry eye, and the curative effect was more favorable than with either medication alone.
本研究旨在探讨玻璃酸钠（SH）联合普拉洛芬治疗干眼症的临床应用。
选取 2020 年 3 月至 2022 年 5 月在昆山市中医院就诊的 117 例干眼症患者，根据治疗方法分为玻璃酸钠组（SH 组）、普拉洛芬组（普拉洛芬组）和玻璃酸钠联合普拉洛芬组（联合组）（每组 39 例）。
SH 组、普拉洛芬组和联合组干眼症的有效率分别为 79.49%、74.36%和 94.87%（ < 0.05）。治疗后，联合组泪膜破裂时间和泪液分泌试验均明显高于其他两组（ < 0.05）。治疗后，联合组角膜荧光素染色和干眼症症状评分明显低于其他两组（ < 0.001）。治疗后，联合组视觉对比敏感度（12 c/d、18 c/d 和 24 c/d）明显高于其他两组（ < 0.001）。联合组的 C 反应蛋白、肿瘤坏死因子-α、干扰素-γ和白细胞介素-1β水平明显低于其他两组（ < 0.001）。治疗后，联合组 VRQOL 生活质量评分明显高于其他两组（ < 0.05）。
SH 联合普拉洛芬治疗干眼症疗效显著，疗效优于单一药物治疗。
